

Vaccination for Herpes virus – Shingrix®



Varicella-Zoster
Virus (VZV)

POWERFUL PROTECTION AGAINST SHINGLES & POSTHERPETIC NEURALGIA (PHN)



More than
90% effective
at preventing shingles
and PHN*

*Clinical trial data



2-DOSE SERIES

FOR STRONG, LONG-LASTING PROTECTION



DOSE 1



2 TO 6
MONTHS
APART



DOSE 2



Recommended for:

- Adults 50 years and older
- Adults 19 years and older who are immunocompromised

HELPS PREVENT



- ✓ Shingles
- ✓ Postherpetic Neuralgia (PHN)

WHO CAN GET IT?



Even if you had shingles before, had chickenpox, or received the older shingles vaccine (Zostavax®).

COMMON SIDE EFFECTS



Sore arm • Fatigue • Headache
Muscle aches • Fever • Chills
(Usually 1–3 days)

NOT A LIVE VACCINE



Shingrix is a non-live vaccine and cannot cause shingles.

TALK TO YOUR HEALTHCARE PROVIDER



See if Shingrix® is right for you.



SHINGRIX® by GSK – STRONGER PROTECTION. BETTER TOMORROW.




Shingrix is a registered trademark of the GSK group of companies.


HERPES ZOSTER (VZV) AND KIDNEY/IN CKD

Shingles (Herpes Zoster) is more common, more severe and more complicated in CKD

WHAT IS HERPES ZOSTER?



Reactivation of Varicella-Zoster Virus (VZV) latent in dorsal root ganglia causes painful, unilateral vesicular rash in a dermatomal distribution.



WHY HIGHER RISK IN CKD?

- Impaired cell-mediated immunity (uremia, inflammation)
- Diabetes mellitus
- Older age
- Malnutrition
- Steroids / Immunosuppressants
- Dialysis
- Kidney transplantation

Incidence:
1.5–2 times higher in CKD
Much higher after transplant



CLINICAL FEATURES

- Painful tingling/burning followed by vesicular rash
- Unilateral, dermatomal
- Common: thoracic dermatomes, trigeminal (ophthalmic)

In CKD patients:

- More extensive lesions
- Delayed healing
- Secondary infection
- Disseminated zoster may occur



RENAL IMPLICATIONS

1. Acute Kidney Injury (AKI)


- Sepsis
- Dehydration
- Rhabdomyolysis (rare)
- Multiorgan involvement



2. Drug-Induced Nephrotoxicity


Mainly due to Antivirals
(Acyclovir, Valacyclovir, Famciclovir)

- Crystal nephropathy
- AKI
- Neurotoxicity in CKD



PREVENTION

- ✓ Dose adjustment as per eGFR
- ✓ Adequate hydration
- ✓ Slow IV infusion



ANTIVIRAL DOSE ADJUSTMENT IN CKD

Antivirals: Acyclovir, Valacyclovir, Famciclovir

eGFR (ml/min/1.73m ²)	What to do
> 50	Usual dose
10 – 50	Reduce dose / increase dosing interval
< 10 or Dialysis	Markedly reduced dose (Give after dialysis)

Overdose can cause:
Confusion, tremors, hallucinations, encephalopathy, crystal nephropathy

COMPLICATIONS IN CKD PATIENTS

Neurological




- Post-herpetic neuralgia
- Meningitis
- Encephalitis

Ocular




- Keratitis
- Uveitis
- Vision loss

Cutaneous



- Disseminated zoster
- Necrotic lesions
- Secondary infection

Visceral (rare)



- Pneumonitis
- Hepatitis
- Vasculopathy

Post-herpetic neuralgia – very common and severe in CKD

DIALYSIS PATIENTS



- Higher incidence
- Severe pain syndromes
- Higher recurrence
- Dose antivirals after dialysis

KIDNEY TRANSPLANT RECIPIENTS



- Very high risk
- Disseminated & visceral disease
- May need IV acyclovir
- Consider reduction of immunosuppression

VACCINATION (PREVENTION)

Recombinant Zoster Vaccine (RZV) – Shingrix®

- ✓ Non-live vaccine
- ✓ Safe in CKD, dialysis, transplant candidates
- ✓ Highly effective



Recommended for:
Adults ≥ 50 years, CKD stages 3–5,
Dialysis patients, Transplant candidates

Schedule:
2 doses
(2–6 months apart)

KEY POINTS (Remember!)



CKD → Impaired Cell-mediated Immunity



↑ Incidence & Severity of Herpes Zoster



Antivirals need Renal Dose Adjustment



Major complication: Post-herpetic Neuralgia



Overdose → Neurotoxicity + Crystal Nephropathy



Best prevention: Shingrix (RZV) Vaccine

One-line Summary:

"Herpes zoster is more frequent and severe in CKD due to impaired cell-mediated immunity; management requires careful antiviral dose adjustment and emphasis on vaccination."

